X4 Pharmaceuticals(XFOR)
$3.12-0.05 (-1.58%)
XFOR
X4 Pharmaceuticals financials statements
$3.12
At close:-0.05 (-1.58%)
Want to see XFOR full AI Analyst Report?
X4 Pharmaceuticals (XFOR) Ratios
1,121 Followers
X4 Pharmaceuticals Ratios
XFOR's free cash flow for Q3 2026 was $-20.19M. For the 2026 fiscal year, XFOR's free cash flow was increased by $0.00 and operating cash flow was $-20.19M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.16 | 3.41 | 5.34 | 5.76 | 6.27 |
| Quick Ratio | 9.98 | 3.33 | 5.34 | 5.76 | 6.27 |
| Cash Ratio | 8.43 | 1.69 | 4.34 | 5.45 | 5.83 |
| Solvency Ratio | -0.75 | -0.29 | -1.05 | -1.14 | -1.67 |
| Operating Cash Flow Ratio | -3.32 | -3.98 | -4.22 | -3.45 | -5.06 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -58.63 | -89.19 |
| Net Current Asset Value | $ 157.41M | $ -12.12M | $ 25.92M | $ 47.14M | $ 35.11M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.53 | 0.40 | 0.25 | 0.34 |
| Debt-to-Equity Ratio | 0.41 | 3.53 | 1.14 | 0.52 | 0.62 |
| Debt-to-Capital Ratio | 0.29 | 0.78 | 0.53 | 0.34 | 0.38 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.77 | 0.52 | 0.30 | 0.34 |
| Financial Leverage Ratio | 1.56 | 6.61 | 2.88 | 2.10 | 1.82 |
| Debt Service Coverage Ratio | -7.78 | -3.18 | -16.44 | -16.84 | -19.06 |
| Interest Coverage Ratio | -9.79 | -4.15 | -18.61 | -21.93 | -23.37 |
| Debt to Market Cap | 0.45 | 0.51 | 0.37 | 0.55 | 0.67 |
| Interest Debt Per Share | 2.04 | 12.96 | 10.81 | 20.57 | 58.55 |
| Net Debt to EBITDA | 2.03 | -0.81 | 0.43 | 0.93 | 0.50 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.18% | 68.83% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -200.16% | -1109.58% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -196.52% | -1078.45% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -247.44% | -1423.58% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -225.44% | -1452.48% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -225.55% | -1464.61% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -225.55% | -1464.61% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.05% | 100.83% | 100.08% | 100.03% | 100.02% |
| EBT Per EBIT | 91.11% | 102.03% | 94.02% | 107.16% | 104.20% |
| Return on Assets (ROA) | -27.27% | -25.57% | -68.70% | -60.33% | -75.69% |
| Return on Equity (ROE) | -42.51% | -169.08% | -197.98% | -126.76% | -137.70% |
| Return on Capital Employed (ROCE) | -32.82% | -32.05% | -86.44% | -65.71% | -82.51% |
| Return on Invested Capital (ROIC) | -32.70% | -31.70% | -85.68% | -64.50% | -81.04% |
| Return on Tangible Assets | -30.02% | -31.45% | -77.88% | -67.90% | -88.85% |
| Earnings Yield | -46.82% | -25.39% | -67.84% | -152.84% | -174.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 61.28 | 1.50 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.10 | 0.09 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 1.40 | 0.28 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 22.07 | 0.53 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.12 | 0.02 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.22 | 0.03 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -65.04 | -2413.95 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 5.96 | 244.09 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 261.28 | 1290.09 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 332.27 | 3948.14 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 267.24 | 1534.19 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.02 | -19.53 | -16.28 | -37.40 | -95.60 |
| Free Cash Flow Per Share | -2.10 | -20.62 | -16.29 | -37.45 | -96.43 |
| Dividend Paid and CapEx Coverage Ratio | -28.54 | -17.87 | -1608.53 | -748.56 | -115.29 |
| Capital Expenditure Coverage Ratio | -28.54 | -17.87 | -1608.53 | -748.56 | -115.29 |
| Operating Cash Flow Coverage Ratio | -1.11 | -1.68 | -1.66 | -2.01 | -1.78 |
| Operating Cash Flow to Sales Ratio | -2.44 | -51.19 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -52.38% | -93.71% | -64.76% | -125.71% | -140.36% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.14 | -3.94 | -1.47 | -0.65 | -0.57 |
| Price-to-Sales (P/S) Ratio | 4.82 | 57.69 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.91 | 6.66 | 2.92 | 0.83 | 0.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.91 | -1.07 | -1.54 | -0.80 | -0.71 |
| Price-to-Operating Cash Flow Ratio | -1.98 | -1.13 | -1.55 | -0.80 | -0.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.06 | 0.02 | 0.01 | -0.02 |
| Enterprise Value Multiple | -0.43 | -6.16 | -1.14 | 0.24 | -0.11 |
| Enterprise Value | 29.41M | 169.90M | 108.19M | -21.88M | 8.95M |
| EV to EBITDA | -0.43 | -6.16 | -1.14 | 0.24 | -0.11 |
| EV to Sales | 0.84 | 66.44 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.33 | -1.23 | -1.12 | 0.28 | -0.13 |
| EV to Operating Cash Flow | -0.34 | -1.30 | -1.12 | 0.28 | -0.13 |
| Tangible Book Value Per Share | 3.78 | -0.78 | 5.69 | 27.50 | 63.45 |
| Shareholders’ Equity Per Share | 4.40 | 3.30 | 8.62 | 35.92 | 86.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.83 | 0.38 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.87 | -5.59 | -17.07 | -45.53 | -119.59 |
| Tax Burden | 1.00 | 1.01 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.13 | 1.31 | 1.06 | 1.04 | 1.04 |
| Research & Development to Revenue | 2.06 | 31.93 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.24 | 24.06 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.12 | 3.21 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.08 | 3.50 | 0.95 | 0.82 | 0.80 |
Currency in USD

